<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03304938</url>
  </required_header>
  <id_info>
    <org_study_id>95010112052</org_study_id>
    <nct_id>NCT03304938</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia</brief_title>
  <official_title>Efficacy and Safety of Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Considering the high prevalence of sleep disturbance in diabetic patients and the
      effectiveness of lavender in treatment of sleep disorders in this study the efficacy of
      Lavender aromatherapy in sleep disorder and metabolic parameters in diabetic patients will be
      investigated. This study is designed as cross-over double-blind placebo-controlled randomized
      clinical trial that 40 diabetic patients with sleep disorder with the inclusion criteria will
      enter into the study and randomly assign to first intervention and first placebo groups.The
      primary outcomes are change in sleep disorder and metabolic parameters that will be evaluated
      at the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2017</start_date>
  <completion_date type="Anticipated">February 18, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>40 diabetic patients with sleep disorder with the inclusion criteria will enter into the crossover study and randomly assign to treatment or placebo groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Lavender Essential oil as medication and almond oil as placebo put in similar dark buttle and the head of placebo bottle aromatized whit Lavender Essential oil and all of participants, care provider, investigator and outcomes assessor will be blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh Insomnia Rating Scale</measure>
    <time_frame>4 weeks</time_frame>
    <description>evaluate the sleep disorder with Pittsburgh Insomnia Rating Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Sugar</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 hours Post Prandial Glucose</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Insulin</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase</measure>
    <time_frame>4 week</time_frame>
    <description>blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>4 week</time_frame>
    <description>Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>4 week</time_frame>
    <description>Body Mass Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>4 week</time_frame>
    <description>Meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hip circumference</measure>
    <time_frame>4 week</time_frame>
    <description>Meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>4 week</time_frame>
    <description>Blood Pressure measurement by digital sphygmometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>4 week</time_frame>
    <description>Blood Pressure measurement by digital sphygmometer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Sleep Disturbance</condition>
  <arm_group>
    <arm_group_label>Lavender oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vehicle (Almond oil)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lavender Oil</intervention_name>
    <description>The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks</description>
    <arm_group_label>Lavender oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks</description>
    <arm_group_label>vehicle (Almond oil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 2

          -  Age between 25-65 years old

          -  Fasting Blood Sugar between 70-130

          -  2 hour post prandial glucose less than 180.

          -  HbA1C less than 7

          -  Sleep disorder according to pittsburgh Insomnia Rating Scale more than 5.

        Exclusion Criteria:

          -  Any systemic illnesses

          -  Use of sedative or antidepressant drugs

          -  Pregnancy

          -  Lactation

          -  History of allergic reaction to Lavender

          -  History of allergic rhinitis, asthma and respiratory disorders

          -  Anosmia

          -  Headache that start with smell

          -  Cigarette smocking or substance abuse

          -  Hospitalization or surgery within 1 months ago.

          -  Work shift
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeinab Nasiri Lari, M.D.</last_name>
      <phone>09173139409</phone>
      <email>dr.znasiri@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2017</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mesbah Shams, MD</investigator_full_name>
    <investigator_title>Associate professor of internal medicine and endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

